• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Minerals
    Tech
    Life Science
    Life Science Market
    Life Science News
    Life Science Stocks
    • Life Science Market
    • Life Science News
    • Life Science Stocks

    Medication Errors Affect 1.2 Million US Hospitalizations a Year, Study Shows

    Written by Charlotte McLeod
    |
    Dec. 10, 2012 12:28PM PST

    Peer-reviewed journal American Health & Drug Benefits reported that its new study indicates that medication errors, specifically those related to injectable medications, affect 1.2 million US-based hospitalizations a year. These errors, also known as preventable adverse drug events, result in an average of $600,000 per year in extra costs per hospital.

    Peer-reviewed journal American Health & Drug Benefits reported that its new study indicates that medication errors, specifically those related to injectable medications, affect 1.2 million US-based hospitalizations a year. These errors, also known as preventable adverse drug events, result in an average of $600,000 per year in extra costs per hospital.

    As quoted in the market news:

    Based on this medication-level analysis of reported harmful errors and the frequency of inpatient administrations with actuarial projections, we estimate that preventable ADEs associated with injectable medications impact 1.2 million hospitalizations annually. Using a matched cohort analysis of healthcare claims as a basis for evaluating incremental costs, we estimate that inpatient preventable ADEs associated with injectable medications increase the annual US payer costs by $2.7 billion to $5.1 billion, averaging $600,000 in extra costs per hospital.

    Click here to read the full American Health & Drug Benefits report.

    The Conversation (0)

    Go Deeper

    AI Powered
    Life Science Outlook: World Edition

    Life Science Outlook: World Edition

    Life Science Outlook

    Life Science Outlook

    Latest News

    BriaCell Announces ESMO 2026 Poster Highlighting Circulating Immune Biomarker Associated with Clinical Outcomes in Metastatic Breast Cancer

    Lexaria's Human Study GLP-1-H26-7 Reaches Full Enrollment and Continues Dosing on Schedule

    BPH Energy Limited September 2026 Quarter Operations Report

    Quarterly Activities/Appendix 4C Cash Flow Report

    More News

    Outlook Reports world

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Life Science Investing Stocks

    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES